Meeting
2014 ASCO Annual Meeting
Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Authors
Karen A. Gelmon
British Columbia Cancer Agency, Vancouver, BC, Canada
Karen A. Gelmon , Judy-Anne W. Chapman , Shuzhen Liu , Margot J. Burnell , Mark Norman Levine , Kathleen I. Pritchard , Timothy Joseph Whelan , Hope S. Rugo , Kathy S. Albain , Edith A. Perez , Shakeel Virk , Patti O'Brien , Lois E. Shepherd , Torsten O. Nielsen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
NCT00014222
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11019)
DOI
10.1200/jco.2014.32.15_suppl.11019
Abstract #
11019
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
BRCA1 like copy number profiles to predict benefit of intensified alkylating chemotherapy in breast cancer.
First Author: Philip C. Schouten
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2016 ASCO Annual Meeting
Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience.
First Author: Susan Faye Dent
Poster
2014 ASCO Annual Meeting
Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.
First Author: Ralph V. Boccia